Table 2.

Publications reporting clinical outcomes by region

	Emerging Asia (n = 14)	Latin America (n = 14)	Middle East (n = 5)	Russia (n = 1)	Turkey (n = 12)	Overall (n = 46)
Outcomes reported, n (%)
Clinical	14 (100.0)	13 (92.9)	5 (100.0)	1 (100.0)	11 (91.7)	44 (95.7)
PRO	–	1 (7.1)	–	–	–	1 (2.2)
Clinical and PRO	–	–	–	–	1 (8.3)	1 (2.2)
Follow-up duration, n (%)
Reported	6 (42.9)	2 (14.3)	3 (60.0)	1 (100.0)	8 (66.7)	20 (43.5)
Not reported	8 (57.1)	12 (85.7)	2 (40.0)	–	4 (33.3)	26 (56.5)
Any effectiveness outcome, n (%)
Reported	14 (100.0)	13 (92.9)	5 (100.0)	1 (100.0)	12 (100.0)	45 (97.8)
Not reported		1 (7.1)		–	–	1 (2.2)
PFS, n (%)
Reported	9 (64.3)	3 (21.4)	5 (100.0)	1 (100.0)	10 (83.3)	28 (60.9)
Not reported	5 (35.7)	11 (78.6)		–	2 (16.7)	18 (39.1)
OS, n (%)
Reported	3 (21.4)	2 (14.3)	3 (60.0)	–	4 (33.3)	12 (26.1)
Not reported	11 (78.6)	12 (85.7)	2 (40.0)	1 (100.0)	8 (66.7)	34 (73.9)
Any safety outcome, n (%)
Reported	12 (85.7)	8 (57.1)	2 (40.0)	1 (100.0)	9 (75.0)	32 (69.6)
Not reported	2 (14.3)	6 (42.9)	3 (60.0)	–	3 (25.0)	14 (30.4)
Incidence of dose modifications, n (%)
Reported	8 (57.1)	7 (50.0)	1 (20.0)	1 (100.0)	4 (33.3)	21 (45.7)
Not reported	6 (42.9)	7 (50.0)	4 (80.0)	–	8 (66.7)	25 (54.3)
Incidence of treatment discontinuation, n (%)
Reported	2 (14.3)	6 (42.9)	2 (40.0)	1 (100.0)	3 (25.0)	14 (30.4)
Not reported	12 (85.7)	8 (57.1)	3 (60.0)	–	9 (75.0)	32 (69.6)
Incidence of grade ≥ 3 neutropenia, n (%)
Reported	9 (64.3)	3 (21.4)	1 (20.0)	–	3 (25.0)	16 (34.8)
Not reported	5 (35.7)	11 (78.6)	4 (80.0)	1 (100.0)	9 (75.0)	30 (65.2)

PFS progression-free survival, OS overall survival